Direct Medical Costs and Their Predictors in Patients With Rheumatoid Arthritis: A Three-Year Study of 7,527 Patients

Arthritis and Rheumatism

Volumn 48, Issue 10, 2003, Pages 2750-2762

  Michaud, Kaleb ^a   Messer, Jodi ^b   Choi, Hyon K ^c   Wolfe, Frederick ^a,d  

^a ARTHRITIS RESEARCH CENTER FOUNDATION   (United States)

^b WICHITA STATE UNIVERSITY   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d UNIVERSITY OF KANSAS SCHOOL OF MEDICINE WICHITA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTIRHEUMATIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGED; AMBULATORY SURGERY; ARTHRITIS; ARTICLE; DIAGNOSTIC IMAGING; DISEASE DURATION; DRUG COST; ETHNIC GROUP; FEMALE; FUNCTIONAL ASSESSMENT; HEALTH CARE UTILIZATION; HEALTH MAINTENANCE ORGANIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; QUESTIONNAIRE; RHEUMATOID ARTHRITIS;

ACTIVITIES OF DAILY LIVING; AGED; ARTHRITIS, RHEUMATOID; COST OF ILLNESS; DIRECT SERVICE COSTS; DRUG COSTS; FEMALE; HEALTH EXPENDITURES; HUMANS; INSURANCE, HEALTH; MALE; MIDDLE AGED; MODELS, ECONOMETRIC; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; QUALITY OF LIFE; QUESTIONNAIRES; SENSITIVITY AND SPECIFICITY; UNITED STATES;

EID: 0142135697     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.11439     Document Type: Article

References (46)

1. Lubeck DP. A review of the direct costs of rheumatoid arthritis: managed care versus fee-for-service settings. Pharmacoeconomics 2001;19:811-8.
2. Meenan RF, Yelin EH, Henke CJ, Curtis DL, Epstein WV. The costs of rheumatoid arthritis: a patient-oriented study of chronic disease costs. Arthritis Rheum 1978;21:827-33.
3. Lubeck DP, Spitz PW, Fries JF, Wolfe F, Mitchell DM, Roth SH. A multicenter study of annual health service utilization and costs in rheumatoid arthritis. Arthritis Rheum 1986;29:488-93.
4. Jonsson B, Larsson SE. Functional improvement and costs of hip and knee arthroplasty in destructive rheumatoid arthritis. Scand J Rheumatol 1991;20:351-7.
5. Magnusson S. Treatment of rheumatoid arthritis: does it affect society's cost for the disease? Br J Rheumatol 1996;35:791-5.
6. McIntosh E. The cost of rheumatoid arthritis. Br J Rheumatol 1996;35:781-90.
7. Yelin E. The costs of rheumatoid arthritis: absolute, incremental, and marginal estimates. J Rheumatol Suppl 1996;44:47-51.
8. Clarke AE, Zowall H, Levinton C, Assimakopoulos H, Sibley JT, Haga M, et al. Direct and indirect medical costs incurred by Canadian patients with rheumatoid arthritis: a 12 year study. J Rheumatol 1997;24:1051-60.
9. Lanes SF, Lanza LL, Radensky PW, Yood RA, Meenan RF, Walker AM, et al. Resource utilization and cost of care for rheumatoid arthritis and osteoarthritis in a managed care setting: the importance of drug and surgery costs. Arthritis Rheum 1997;40:1475-81.
10. Van Jaarsveld CH, Jacobs JW, Schrijvers AJ, Heurkens AH, Haanen HC, Bijlsma JW. Direct cost of rheumatoid arthritis during the first six years: a cost-of-illness study. Br J Rheumatol 1998;37:837-47.
11. Newhall-Perry K, Law NJ, Ramos B, Sterz M, Wong WK, Bulpitt KJ, et al, Western Consortium of Practicing Rheumatologists. Direct and indirect costs associated with the onset of seropositive rheumatoid arthritis. J Rheumatol 2000;27:1156-63.
12. Yelin E, Wanke LA. An assessment of the annual and long-term direct costs of rheumatoid arthritis: the impact of poor function and functional decline. Arthritis Rheum 1999;42:1209-18.
13. Gabriel SE, Crowson CS, Campion ME, O'Fallon WM. Direct medical costs unique to people with arthritis. J Rheumatol 1997;24:719-25.
14. Kobelt G, Jönsson L, Lindgren P, Young A, Eberhardt K. Modeling the progression of rheumatoid arthritis: a two-country model to estimate costs and consequences of rheumatoid arthritis. Arthritis Rheum 2002;46:2310-9.
15. Pugner KM, Scott DI, Holmes JW, Hieke K. The costs of rheumatoid arthritis: an international long-term view. Semin Arthritis Rheum 2000;29:305-20.
16. Wolfe F, Anderson J, Burke TA, Arguelles LM, Pettitt D. Gastroprotective therapy and risk of gastrointestinal ulcers: risk reduction by COX-2 therapy. J Rheumatol 2002;29:467-73.
17. Wolfe F, Flowers N, Burke TA, Arguelles LM, Pettitt D. Increase in lifetime adverse drug reactions, service utilization, and disease severity among patients who will start COX-2 specific inhibitors: quantitative assessment of channeling bias and confounding by indication in 6689 patients with rheumatoid arthritis and osteoarthritis. J Rheumatol 2002;29:1015-22.
18. Wolfe F, Flowers N, Anderson J. The National Rheumatic Disease Data Bank: case mix and severity characteristics of patients in rheumatological practice [abstract]. Arthritis Rheum 1998;41 Suppl 9:S132.
19. Fries JF, Spitz PW, Young DY. The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales. J Rheumatol 1982;9:789-93.
20. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137-45.
21. Wolfe F, Hawley DJ, Wilson K. The prevalence and meaning of fatigue in rheumatic disease. J Rheumatol 1996;23:1407-17.
22. Meenan RF, Gertman PM, Mason JH, Dunaif R. The Arthritis Impact Measurement Scales: further investigations of a health status measure. Arthritis Rheum 1982;25:1048-53.
23. Meenan RF. The AIMS approach to health status measurement: conceptual background and measurement properties. J Rheumatol 1982;9:785-8.
24. Stucki G, Liang MH, Stucki S, Brühlmann P, Michel BA. A self-administered Rheumatoid Arthritis Disease Activity Index (RADAI) for epidemiologic research: psychometric properties and correlation with parameters of disease activity. Arthritis Rheum 1995;38:795-8.
25. Fransen J, Häuselmann H, Michel BA, Caravatti M, Stucki G. Responsiveness of the self-assessed Rheumatoid Arthritis Disease Activity Index to a flare of disease activity. Arthritis Rheum 2001;44:53-60.
26. Fransen J, Langenegger T, Michel BA, Stucki G. Feasibility and validity of the RADAI, a self-administered rheumatoid arthritis disease activity index. Rheumatology (Oxford) 2000;39:321-7.
27. McHorney CA, Ware JE Jr, Lu JF, Sherbourne CD. The MOS 36-item Short-Form Health Survey (SF-36). III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care 1994;32:40-66.
28. Ware JE, Sherbourne CD. The MOS 36-Item Short-Form Health Survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473-83.
29. Fransen M, Edmonds J. Reliability and validity of the EuroQol in patients with osteoarthritis of the knee. Rheumatology (Oxford) 1999;38:807-13.
30. Kobelt G, Eberhardt K, Jönsson L, Jönsson B. Economic consequences of the progression of rheumatoid arthritis in Sweden. Arthritis Rheum 1999;42:347-56.
31. EuroQol Group. EuroQol: a new facility for the measurement of health-related quality of life. Health Policy 1990;16:199-208.
32. Choi HK, Michaud K, Wolfe F. Utility measures in rheumatic diseases [abstract]. Arthritis Rheum 2002;46 Suppl 9:S76.
33. Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ 2002;21:271-92.
34. Choi HK, Hernan MA, Seeger JD, Robins JM, Wolfe F. Methotrexate therapy and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002;359:1173-7.
35. Lerner D, Reed JI, Massarotti E, Wester LM, Burke TA. The Work Limitations Questionnaire's validity and reliability among patients with osteoarthritis. J Clin Epidemiol 2002;55:197-208.
36. Lerner D, Amick BC III, Rogers WH, Malspeis S, Bungay K, Cynn D. The Work Limitations Questionnaire. Med Care 2001;39:72-85.
37. Centers for Medicare and Medicaid Services. Medicare and Medicaid statistics. Baltimore: 2002.
38. Drug topics red book. Montvale (NJ): Medical Economics; 2001.
39. Goodson N. Coronary artery disease and rheumatoid arthritis. Curr Opin Rheumatol 2002;14:115-20.
40. Del Rincón ID, Williams K, Stern MP, Freeman GL, Escalante A. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001;44:2737-45.
41. Dessein PH, Stanwix AE, Moomal Z. Rheumatoid arthritis and cardiovascular disease may share similar risk factors. Rheumatology (Oxford) 2001;40:703-4.
42. Gabriel SE. The epidemiology of rheumatoid arthritis. Rheum Dis Clin North Am 2001;27:269-81.
43. Stata Corporation. Stata statistical software: Release 7.0. College Station (TX): 2001.
44. Tomz M, Wittenberg J, King G. CLARIFY: software for interpreting and presenting statistical results. 1998 (1.2).
45. Wolfe F, Zwillich SH. The long-term outcomes of rheumatoid arthritis: a 23-year prospective, longitudinal study of total joint replacement and its predictors in 1,600 patients with rheumatoid arthritis. Arthritis Rheum 1998;41:1072-82.
46. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.